Company: Bristol-Myers Squibb
Liaison(s): Mary Moore, Jennifer L. Liu
Bristol-Myers Squibb ( BMS ) is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. BMS is a differentiated company, led by its unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. BMS medicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through its R&D organization, BMS has built a sustainable pipeline of potential therapies, and partners with external innovation to broaden and accelerate its work.1 BMS is committed to providing innovative, high-quality medicines that strive to address the unmet medical needs of patients with serious diseases. Additionally, BMS wishes to advance science through supporting novel, independent research that addresses unmet need surrounding its products and therapeutic areas. Independent research may be defined within the industry as Investigator Sponsored Research ( ISR ), Investigator Initiated Research ( IIR ), Investigator Sponsored Trials ( IST ) or Investigator Initiated Trials ( IIT ).2 This Keck Graduate Institute Team Masters Project ( KGI TMP ) is focused on creating a better understanding of the landscape of Investigator Sponsored Research ( ISR ) in immuno-oncology. To complete this project, the KGI TMP team developed a process for gathering data based on information in the public domain. After completing a pilot phase, the team applied their methodology to create a database of ISRs across several products and established a go-forward framework for refreshing the landscape. At the conclusion of the project, the KGI TMP team provided BMS with a detailed database and analysis of the ISR landscape in immuno-oncology.